IQM-QUANTUM-COMPUTERS
21.12.2021 12:02:08 CET | Business Wire | Press release
IQM France will collaborate closely with customers in the aviation, space, and cybersecurity verticals using IQM’s co-design approach. IQM is also part of Atos’s Scaler program, and this subsidiary will focus further on HPC integration and offer quantum accelerators to supercomputing centers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211221005096/en/
Through this new subsidiary, IQM joins the French quantum ecosystem that consists of world-renowned universities and research institutes and a fast-growing start-up scene and provides excellent industry infrastructure. IQM’s expertise and reach, combined with this vibrant ecosystem, will create significant opportunities for partnerships and collaboration in Europe and across the globe.
In the first phase, IQM France aims to tap into the extended talent pool of quantum students, postdocs, and experienced professionals. The plan is to start with a core team of business developers, products managers, quantum scientists, and engineers in 2022. The aim is to create a center of excellence in specific industry verticals and systematically grow in subsequent years.
IQM France’s office will be in the central hub at Spaces Les Halles on 40 rue du Louvre, Paris. Dr. Björn Pötter will take on the role of Country Manager for France in addition to his role as Global Head of Products at IQM. Dr. Pötter, who recently joined IQM, holds a PhD in physics and has extensive experience with digital technologies in the Aerospace and Cybersecurity industries. Dr. Pötter has held several international leadership positions with a focus on technology and innovation, among others at Airbus.
“I am excited to see IQM start its French operations in the Paris region, where I have been working for several years. The Paris team will build the bridge between the various IQM teams around Europe and the high-quality French quantum ecosystem. The team will enable local operations for collaborative IQM projects in strategic industrial areas,” said Dr. Pötter.
Speaking about this announcement, Dr. Jan Goetz, CEO and cofounder of IQM, said, “France plays an integral role in the quantum scientific research and has been on our roadmap for a while. I’m extremely pleased to announce the operations of our French entity today, especially at a time when the French quantum plan is gaining momentum. This French subsidiary together with our co-design teams in Bilbao and Munich and the quantum hardware and software teams in Espoo, Finland, will strengthen European quantum leadership.”
“The Paris region is proud to welcome a major European quantum computing player to the epicenter of the French quantum ecosystem. We support IQM’s local setup and growth to help them make the most of the excellent research and talent available. We are also convinced that IQM will thrive in France’s #1 aerospace region,” said Alexandra Dublanche, President of Choose Paris Region and Vice President in charge of Recovery, Attractiveness, Economic Development, and Innovation of the Paris Region.
“We are very thankful to Choose Paris Region and also Business France for the active, pragmatic, and timely support, which allowed us to set up IQM France in a very short time,” Dr. Pötter added.
In March 2021, Dr. Goetz presented on deep tech and building global tech leaders’ topics at the Scale-Up Europe event, where President Emmanuel Macron was an attendee. This presentation was part of the Scale-up Europe initiative facilitated by Sifted.
About IQM Quantum Computers:
IQM is a Pan-European leader in quantum computers.
IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers the quantum advantage through a unique application-specific co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building a quantum computer in Germany that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich, and Espoo and employs over 130 people. More information: www.meetiqm.com
Links to the quoted press releases:
- IQM opens its exclusive quantum fabrication facility in Finland
- IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
- IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.
Registered office:
IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland
Choose Paris Region is the agency in charge of promoting the attractiveness of the Paris region in terms of international business. The agency works in partnership with all the region’s key players to create an appealing and coherent territorial offer, ensure promotion of the region, and offer a tailor-made service to support international businesses and professionals in their expansion.
https://www.chooseparisregion.org/
Headquarters:
Choose Paris Region, 18 rue de Londres, 75009 Paris
contact@chooseparisregion.org - +33 800 019 011
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom